HomeMBIO • NASDAQ
Follow
Mustang Bio Inc
Previous close
$0.94
Day range
$1.01 - $1.07
Year range
$0.90 - $8.17
Market cap
10.75M USD
Avg Volume
257.62K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 8.86M | -54.43% |
Net income | -8.62M | 56.12% |
Net profit margin | — | — |
Earnings per share | -0.71 | 73.70% |
EBITDA | -8.57M | 54.17% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 6.23M | -91.76% |
Total assets | 17.74M | -80.80% |
Total liabilities | 17.62M | -61.82% |
Total equity | 123.00K | — |
Shares outstanding | 10.33M | — |
Price to book | 94.00 | — |
Return on assets | -115.59% | — |
Return on capital | -481.04% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -8.62M | 56.12% |
Cash from operations | -7.25M | 52.55% |
Cash from investing | -30.00K | 92.86% |
Cash from financing | 3.96M | 395,500.00% |
Net change in cash | -3.33M | 78.81% |
Free cash flow | -4.96M | 52.38% |
About
Mustang Bio is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
80